Sara Tolaney, MD, MPH
Enriched profileChief, Division of Breast Oncology, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School; Associate Director, Susan F. Smith Center for Women's Cancers · Dana-Farber Cancer Institute
Sara Tolaney is Chief, Division of Breast Oncology, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School; Associate Director, Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute. OpenAlex indexes 1,337 publications with 37,487 citations (h-index 85); ClinicalTrials.gov lists 22 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Sara Tolaney as a Highly Cited Researcher (Clinical Medicine, 2023-2025; Cross-Field, 2022).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Sara Tolaney, MD, is Chief, Division of Breast Oncology, Dana-Farber Cancer Institute. The public record shows 1,337 publications with 37,487 citations (h-index 85), centered on Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology. It also documents an investigator role on 22 registered clinical trials, industry payments reported by 40 companies, 1 NIH-funded awards (2024–2026).
- Most recent indexed publication: 2026 · JNCI cancer spectrum
- Top research focus: Advanced Breast Cancer Therapies
- 22 registered trials on ClinicalTrials.gov
- Open Payments reporting from 40 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 109 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 359.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 22 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
- Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
- ATEMPT 2.0: Adjuvant T-DM1 vs TH
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 27 Aug 2026
40 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- F. Hoffmann-La Roche AGProgram year202511 payments$29,218openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year202515 payments$24,349openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202511 payments$21,703openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor65%Verzenio54%Ibrance46%Part D<11 patientsAromatase Inhibitor35%Letrozole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.
JNCI cancer spectrum
Article2026 - The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets.
Clinical cancer research
Article2026 - Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Journal of clinical oncology
Article2026 - Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.
Nature communications
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/sara-tolaney-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Sara-Tolaney
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/stolaney1
Mentions by others
where others cite or feature them- Instagram
instagram.com/danafarber_breast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
mantacares.com/blogs/podcast-landing/patient-from-hell-podcast-ep-82-rewriting-the-story-of-triple-negative-breast-cancer-with-dr-sara-tolaney
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mantacares.com ↗ - Other
vjoncology.com/speaker/sara-tolaney
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjoncology.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Residency
Internal Medicine, Johns Hopkins University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Fellowship
Hematology and Medical Oncology, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Board Certified: Internal Medicine
Hematology, Medical Oncology (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Member
National Cancer Institute Breast Cancer Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Vice Chair for Late-Stage Development in Breast Cancer
Alliance for Clinical Trials in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Chair
multiple phase 3 breast cancer clinical trials (e.g., DESTINY-Breast09, ASCENT-04, ASCENT-03, TROPICS-02, ATEMPT)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Brigham and Women's Hospital
Department of Medical Oncology, Boston, MA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗ - Co-Leader
Breast Cancer Research Program, Dana-Farber/Harvard Cancer Center; Member, Center Scientific Council
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Podcast guest discussing tucatinib/TDXd for CNS metastases in HER2+ breast cancer
Breast Cancers Today podcast
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute